Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hygeia Healthcare Holdings Co., Limited (6078.HK)
Shanghai, CN
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.26% | -6.58% | -16.16% | -27.33% | -23.66% | -22.30% | -37.01% | -79.11% | -89.25% | -62.88% | -62.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 9 | 0 |
| Hold | 4 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-9.8% Q4'25: -12.9% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-71.6% Q4'25: -123.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+17.5% ★ Q4'25: +10.8% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+17.1% ★ Q4'25: +16.5% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+4.8% Q4'25: +9.4% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%-1.7% ★ Q4'25: -2.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.57× Q4'25: 1.33× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 8 EPS Ana. |
Dec 2027 14 Rev. Ana. 8 EPS Ana. |
Dec 2028 9 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.40B
est: 1.68B (-16.3%)
|
2.32B
est: 2.94B (-21.4%)
|
3.20B
est: 3.67B (-13.0%)
|
4.08B
est: 4.37B (-6.7%)
|
4.45B
est: 5.08B (-12.5%)
|
4.01B
est: 4.06B (-1.2%)
|
4.49B
4.15B – 4.67B
+10.6% YoY
|
4.87B
4.24B – 5.64B
+8.5% YoY
|
5.28B
4.73B – 5.81B
+8.3% YoY
|
| EBITDA |
385.36M
est: 439.94M (-12.4%)
|
623.67M
est: 72.93M (+755.2%)
|
868.43M
est: 97.33M (+792.3%)
|
1.11B
est: 1.12B (-0.5%)
|
999.10M
est: 1.36B (-26.4%)
|
951.82M
est: 1.04B (-8.1%)
|
1.15B
1.06B – 1.19B
+10.6% YoY
|
1.24B
1.08B – 1.44B
+8.5% YoY
|
1.35B
1.21B – 1.48B
+8.3% YoY
|
| EBIT |
318.13M
est: 364.86M (-12.8%)
|
525.61M
est: 228.03M (+130.5%)
|
735.77M
est: 304.31M (+141.8%)
|
899.26M
est: 902.71M (-0.4%)
|
822.66M
est: 1.10B (-25.2%)
|
684.14M
est: 838.07M (-18.4%)
|
927.23M
856.08M – 964.22M
+10.6% YoY
|
1.01B
875.02M – 1.17B
+8.5% YoY
|
1.09B
976.14M – 1.20B
+8.3% YoY
|
| Net Income |
170.09M
est: 296.84M (-42.7%)
|
441.46M
est: 52.05M (+748.1%)
|
476.78M
est: 586.71M (-18.7%)
|
682.93M
est: 682.17M (+0.1%)
|
598.26M
est: 758.53M (-21.1%)
|
164.53M
est: 310.23M (-47.0%)
|
511.82M
458.64M – 565.00M
+65.0% YoY
|
609.99M
545.72M – 674.25M
+19.2% YoY
|
643.17M
572.53M – 896.38M
+5.4% YoY
|
| SGA |
152.43M
est: 169.84M (-10.2%)
|
225.42M
est: 170.46M (+32.2%)
|
292.95M
est: 227.49M (+28.8%)
|
462.75M
est: 450.44M (+2.7%)
|
424.94M
est: 548.46M (-22.5%)
|
469.56M
est: 418.19M (+12.3%)
|
462.67M
427.17M – 481.13M
+10.6% YoY
|
502.21M
436.62M – 581.45M
+8.5% YoY
|
544.07M
487.08M – 599.15M
+8.3% YoY
|
| EPS |
0.38
est: 0.47 (-19.5%)
|
0.71
est: 0.95 (-24.9%)
|
0.77
est: 1.02 (-24.6%)
|
1.08
est: 1.08 (0.0%)
|
0.95
est: 1.23 (-22.8%)
|
0.27
est: 0.50 (-46.3%)
|
0.85
0.74 – 0.91
+69.9% YoY
|
0.99
0.88 – 1.09
+15.8% YoY
|
1.14
0.93 – 1.45
+15.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.28% | 184.7K | 0.59% |
| 2 | Goldman Sachs Innovate Equity ETF GINN | 0.06% | 124.6K | 0.50% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.04% | 27.7K | 0.74% |
| 4 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 113.4K | 0.72% |
| 5 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 212.9K | 0.65% |
| 6 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.03% | 30.4K | 0.42% |
| 7 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 87.7K | 0.74% |
| 8 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 109.4K | 0.55% |
| 9 | State Street SPDR S&P China ETF GXC | 0.01% | 61.8K | 0.59% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.55M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huanhuan Cheng | Executive Director & Joint Company Secretary | 2M | female |
| Ai Ren | Co-CEO & Executive Director | 2M | male |
| Yiwen Zhu | Chairman & Co-CEO | 2M | male |
| Wenshan Zhang | Director of Research & Development, Manufacturing and Executive Director | 1M | male |
| Hui Jiang | Director of Radiotherapy Division & Executive Director | 901.4K | female |
| Kwok Yin Lau | Joint Company Secretary | — | male |
| Xi Ping Jin | Accounting Supervisor | — | — |
| Xue Yu | Financial Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6078.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
